By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of ...

By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Some patients dropped out of the trial early because they had lost so much weight.

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

By Maggie Fick LONDON, Dec 11 (Reuters) - Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish ...

Food-packed tables and endless spirits can present a special challenge for those taking GLP-1 medications like Wegovy, ...

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...